Evaluation of a new agent in the treatment of parkinsonism.
D002317:Cardiovascular Agents; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000628:therapy*; D020734:Parkinsonian Disorders; D010880:Piperidines
D002317:Cardiovascular Agents; D009125:Muscle Relaxants, Central; D010880:Piperidines
MUSCLE RELAXANTS/therapeutic use; PARALYSIS AGITANS/therapy; PIPERIDINES